Dana-Farber Cancer Institute
George D. Demetri, MD, FACP, FASCO,FAACR is Senior Vice President for Experimental Therapeutics and Director of the Sarcoma Center at the Dana-Farber Cancer Institute as well as a Professor of Medicine and Co-Director of the Ludwig Center at Harvard Medical School. He received his undergraduate degree in Biochemistry from Harvard College, followed by a research fellowship at the Universite of Besancon, France before attending Stanford University School of Medicine. Subsequently, he completed residency and Chief Residency in Internal Medicine at the University of Washington Hospitals in Seattle, then Fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School (HMS). He was a pioneer in the development of imatinib, the first cancer therapy targeting gastrointestinal stromal tumor (GIST) as a molecularly-defined subset of sarcomas. Subsequently, his work has contributed to the U.S. FDA and worldwide regulatory approvals of several other “smart drugs” for cancer, including sunitinib and regorafenib for GIST, tazemetostat for epithelioid sarcomas, as well as pazopanib, eribulin and trabectedin for other sarcomas. In a related contribution, Dr. Demetri served on the Scientific Advisory Board for Plexxikon to develop the first mutant BRAF inhibitor, vemurafenib, as the first mutation-targeted therapy for melanomas. He serves on the Board of Directors of a Cambridge Massachusetts-based biotech firm (Blueprint Medicines) and recently co-founded a biotech (IDRX) to develop novel treatment combinations for GIST and other malignancies.
Disclosure information not submitted.
Friday, September 23, 2022
10:15 AM – 12:10 PM
Friday, September 23, 2022
11:20 AM – 11:40 AM
Friday, September 23, 2022
11:40 AM – 12:10 PM